title: Evaluation of the effects of a VEGFR-2 inhibitor compound on alanine aminotransferase gene expression and enzymatic activity in the rat liver.
abstract: BACKGROUND
  Traditional assessment of drug-induced hepatotoxicity includes morphological examination of the liver and evaluation of liver enzyme activity in serum. The objective of the study was to determine the origin of drug-related elevation in serum alanine aminotransferase (ALT) activity in the absence of morphologic changes in the liver by utilizing molecular and immunohistochemical techniques.
  
  
  METHODS
  Sixteen female Sprague-Dawley rats were divided into 2 groups (control and treated, n = 4 per group) and treated rats were dosed orally twice daily (400 mg/kg/day) for 7 days with a VEGFR-2 compound (AG28262), which in a previous study caused ALT elevation without morphological changes. Serum of both treated and control animals were evaluated on day 3 of treatment and at day 8. Three separate liver lobes (caudate, right medial, and left lateral) were examined for determination of ALT tissue activity, ALT gene expression and morphological changes.
  
  
  RESULTS
  ALT activity was significantly (p < 0.01) elevated on day 3 and further increased on day 8. Histologic changes or increase in TUNEL and caspase3 positive cells were not observed in the liver lobes examined. ALT gene expression in the caudate lobe was significantly up-regulated by 63%. ALT expression in the left lateral lobe was not significantly affected. Statistically significant increased liver ALT enzymatic activity occurred in the caudate (96%) and right medial (41%) lobes but not in the left lateral lobe.
  
  
  CONCLUSIONS
  AG28262, a VEFG-r2 inhibitor, causes an increase in serum ALT, due in part to both gene up-regulation. Differences between liver lobes may be attributable to differential distribution of blood from portal circulation. Incorporation of molecular data, such as gene and protein expression, and sampling multiple liver lobes may shed mechanistic insight to the evaluation of hepatotoxicity.
authors.affiliation: Drug Safety Research & Development, Pfizer Inc,, La Jolla, CA, Michigan State University, USA. cfuentea@ucalgary.ca.
authors.forename: Carmen
authors.initials: C
authors.lastname: Fuentealba
authors.forename: Monali
authors.initials: M
authors.lastname: Bera
authors.forename: Bart
authors.initials: B
authors.lastname: Jessen
authors.forename: Fred
authors.initials: F
authors.lastname: Sace
authors.forename: Greg J
authors.initials: GJ
authors.lastname: Stevens
authors.forename: Dusko
authors.initials: D
authors.lastname: Trajkovic
authors.forename: Amy H
authors.initials: AH
authors.lastname: Yang
authors.forename: Winston
authors.initials: W
authors.lastname: Evering